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New antivirals that could overcome these shortcomings are thus on
the wish list as well.
This report on VIS410 summarizes the ﬁndings of a double-blind,
placebo-controlled phase 1 study that was performed in healthy adults
(Wollacott et al., 2016). Volunteers received one dose of either placebo
(n= 11) or 2, 5, 15, 30 or 50mg/kg of VIS410 (n=30 in total) by intra-Inﬂuenza affects us all. This respiratory disease is caused by inﬂuen-
za A and B viruses in humans and is well known to ‘return’ each year
during the winter season in temperate climate zones. For most people
“the ﬂu” is a discomforting and self-limiting condition that keeps one
in bed for a few days with fever, a sore throat, headache and muscle
aches. Severe disease or even mortality occurs in a very low proportion
of inﬂuenza virus-infected individuals: on average less than 0.1% in the
case of seasonal inﬂuenza. During some of the past pandemics this
percentage was signiﬁcantly higher. People with pre-existing chronic
pulmonary disease and the elderly have an increased risk of developing
potentially life-threatening complications following infection with
inﬂuenza virus.
In this issue of EBioMedicine, Visterra Inc., a biotechnology company
based in Cambridge (Massachusetts, USA), reports on the safety and
bio-distribution of a new drug candidate against inﬂuenza A
(Wollacott et al., 2016). The tested drug is a human monoclonal anti-
body, named VIS410, that reacts with a conserved epitope in the stem
of inﬂuenza A hemagglutinin (HA). Vaccines and antivirals are already
marketed for inﬂuenza. Close to one billion doses of licensed inﬂuenza
vaccines are used prophylactically each year. These vaccines are safe
and can reduce disease and death caused by inﬂuenza viruses (Beyer
et al., 2013). In addition, there are a number of small molecule antivirals
against inﬂuenza on the market. These are most effective when applied
prophylactically or as soon as possible after symptoms start (Jefferson
et al., 2014). However, these interventions are not fail-proof and there
are numerous efforts to develop inﬂuenza vaccines with increased,
prolonged or broadened protective potential. Furthermore, the current-
ly used anti-inﬂuenza drugs often give rise to resistant viruses and re-om.2016.02.021.
. This is an open access article underquire daily intake to sustain effective concentrations in circulation.
venous infusion over a minimum period of 2 h. The overall conclusion
was that VIS410 was generally safe, although gastrointestinal symp-
toms (notably diarrhea)were reported in 10 out of 30 VIS410 recipients
and none in the placebo group. Maximum serum concentrations of
VIS410 ranged from 58.6 μg/mL at a 2 mg/kg dose to 1316 μg/mL at a
50 mg/kg dose and these were reached almost immediately after
infusion. As expected for an IgG antibody, the serum half-life of the
drug was approximately 14 days.
There is a tremendous interest in the development of broad inﬂuen-
za virus-neutralizingmonoclonal antibodies and in vaccines that can in-
duce such antibodies (Kanekiyo et al., 2013). Several companies,
including Genentech and Crucell have completed early phase clinical
studies with their candidate broadly reactive anti-HA stem human
monoclonal antibodies. VIS410, however, is not just another HA-stem
speciﬁc humanmonoclonal antibody. This human IgG1monoclonal an-
tibody is the result of man-made design and protein engineering and so
is not derived from a natural source. In addition, VIS410's epitope in HA
is based on a predictionmade by an algorithm that searches for patches
of surface exposed amino acids that are involved in multiple inter-
residue interactions. Such amino acids are part of a so called signiﬁcant
interaction network (SIN) and are therefore likely to contribute crucial-
ly to the folding, stability and function of a protein. This implies a low
tolerance for mutations at positions with a high SIN score and thus, in
the context of inﬂuenza HA, high sequence conservation. VIS410 targets
a conformational epitope in the stem of HA of group 1 (e.g. H1, H2, H5),
and group 2 (e.g. H3 and H7) inﬂuenza viruses. The antibody can neu-
tralize H1N1 and H3N2 but not H7N9 viruses in vitro (Baranovich
et al., 2016; Tharakaraman et al., 2015). Nevertheless, VIS410 treatment
protects mice against challenge with H7N9 virus and so, like other
broadly-neutralizing antibodies, most likely depends on cooperation
with Fcγ Receptors for in vivo protection (DiLillo et al., 2014). Whether
inﬂuenza A viruses can evolve to escape from VIS410 protection
remains to be determined.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
17X. Saelens / EBioMedicine 5 (2016) 16–17From a cost–beneﬁt perspective the use of a recombinant monoclo-
nal antibody-based therapy against inﬂuenza could be considered for
elderly individuals because inﬂuenza-associated hospitalizations are
highest in this age group (Thompson et al., 2004). In their phase I
study report, Wollacott et al. applied a microsimulation method to esti-
mate the potential beneﬁt of prophylactic use of VIS410 in different age
groups (Wollacott et al., 2016). This simulation suggested that starting
prophylactic treatment eight weeks prior to the peak of an inﬂuenza
epidemic, could reduce the risk of inﬂuenza A-related hospitalization
of elderly individuals by 30.9%. If true in real life this would be impres-
sive. Interestingly, elderly people already have higher concentrations
of HA-stem speciﬁc antibodies in circulation compared to younger
people (Nachbagauer et al., 2016). However, the levels of these natural
antibodies are probably far below the levels of 1–2 mg/mL as proposed
byWollacott et al., so infusion of gram amounts of VIS410 per individual
would be needed to reach that concentration. To apply this amount of
antibody to even a fraction of the population will require considerable
production and downstream processing facilities. Another concern is
that VIS410 does not work against inﬂuenza B. Even though inﬂuenza
B attack rates in the elderly are lower than those of H1N1 and H3N2
(Bedford et al., 2015), the proposed prophylactic treatment should
ultimately also include an antibody against this virus.
Antibodies are among the most frequently used protein therapeu-
tics; mostly for the treatment of cancer and chronic inﬂammatory
diseases. Interest to develop antibodies to prevent and treat infectious
diseases is clearly on the rise. Given the extraordinary antigenic ﬂexibil-
ity of human inﬂuenza viruses, it will be wise to bet on more than one
horse and to come up with an antibody combination therapy that
targets multiple conserved epitopes in the viral membrane proteins.
VIS410 may well ﬁt in such a blend.Competing Interest
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